COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
作者信息
Roeker Lindsey E, Knorr David A, Thompson Meghan C, Nivar Mariely, Lebowitz Sonia, Peters Nicole, Deonarine Isaac, Momotaj Saddia, Sharan Saumya, Chanlatte Vanessa, Hampton Bianca, Butala Liana, Amato Lindsay, Richford Angela, Lunkenheimer Jessica, Battiato Kristen, Laudati Carissa, Mato Anthony R
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ, USA.
出版信息
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
Abstract
摘要
相似文献
1
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
2
Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者接种第二剂BNT162b mRNA新冠疫苗100天后的抗体持久性
Leukemia. 2021 Sep;35(9):2727-2730. doi: 10.1038/s41375-021-01380-5. Epub 2021 Aug 10.
3
COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.2019冠状病毒病疫苗接种：慢性淋巴细胞白血病患者疫苗接种失败风险评估
Hematol Oncol. 2021 Dec;39(5):712-714. doi: 10.1002/hon.2916. Epub 2021 Aug 30.
4
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.接受针对新冠病毒病全剂量疫苗接种的B细胞恶性肿瘤患者血清阳性率低且中和率未达最佳水平。
Br J Haematol. 2021 Dec;195(5):706-709. doi: 10.1111/bjh.17836. Epub 2021 Sep 21.
5
mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.慢性淋巴细胞白血病患者接种新型冠状病毒 mRNA 疫苗：一项系统评价与荟萃分析。
Eur J Haematol. 2022 Mar;108(3):264-267. doi: 10.1111/ejh.13729. Epub 2021 Dec 13.
6
Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者 COVID-19 疫苗失败的原因和后果。
Eur J Haematol. 2022 Feb;108(2):91-98. doi: 10.1111/ejh.13722. Epub 2021 Dec 5.
7
COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis.接受透析患者的新冠疫苗类型与体液免疫反应
J Am Soc Nephrol. 2022 Jan;33(1):33-37. doi: 10.1681/ASN.2021070936. Epub 2021 Oct 13.
8
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.接种BNT162b2和mRNA-1273后新型冠状病毒2型抗体反应的比较
JAMA. 2021 Oct 19;326(15):1533-1535. doi: 10.1001/jama.2021.15125.
9
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.BNT162b2 mRNA 抗 SARS-CoV-2 疫苗接种健康和免疫功能低下个体的 NK 细胞频率、功能及其与疫苗结果的相关性。
Mol Med. 2022 Feb 8;28(1):20. doi: 10.1186/s10020-022-00443-2.
10
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.评估新冠疫苗需要标准化的中和抗体检测。
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
引用本文的文献
1
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染对B细胞淋巴增殖性疾病患者双特异性抗体治疗的影响。
Blood Adv. 2025 Aug 26;9(16):4180-4189. doi: 10.1182/bloodadvances.2024015406.
2
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.奥密克戎时代替沙格韦单抗-西加韦单抗用于血液系统、免疫功能低下患者的SARS-CoV-2暴露前预防
Eur J Haematol. 2025 Apr;114(4):690-699. doi: 10.1111/ejh.14377. Epub 2025 Jan 6.
3
COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?接受维奈克拉治疗的慢性淋巴细胞白血病患者中的 COVID-19：抗 CD20 抗体的作用是什么？
Blood Adv. 2025 Jan 14;9(1):162-165. doi: 10.1182/bloodadvances.2024013792.
4
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.免疫预测因子在淋巴瘤和慢性淋巴细胞白血病患者中的疫苗反应。
J Infect Dis. 2024 Jul 25;230(1):15-27. doi: 10.1093/infdis/jiae106.
5
Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病的疫苗挑战：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫接种对慢性淋巴细胞白血病患者疗效的全面探索
Ann Hematol. 2024 Dec;103(12):4971-4980. doi: 10.1007/s00277-024-05869-8. Epub 2024 Jul 15.
6
Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis.与健康对照相比，新冠病毒疫苗在血液系统恶性肿瘤患者中的疗效：一项系统评价和荟萃分析
JMA J. 2024 Apr 15;7(2):153-171. doi: 10.31662/jmaj.2023-0171. Epub 2024 Apr 1.
7
Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG).老年淋巴瘤患者新型冠状病毒肺炎感染的多中心研究：代表江苏省淋巴瘤协作组（JCLG）
Ann Hematol. 2024 Dec;103(12):5713-5727. doi: 10.1007/s00277-024-05744-6. Epub 2024 Apr 22.
8
Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia.替沙格韦单抗-西加韦单抗单克隆抗体预先暴露预防对慢性淋巴细胞白血病患者中出现的 SARS-CoV-2 耐药变异株的疗效。
Acta Haematol. 2024;147(6):634-645. doi: 10.1159/000537690. Epub 2024 Mar 12.
9
Vaccinations in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者的疫苗接种。
Semin Hematol. 2024 Apr;61(2):131-138. doi: 10.1053/j.seminhematol.2024.01.003. Epub 2024 Jan 6.
10
IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients.淋巴瘤患者感染 SARS-CoV-2 后的 IgG 抗体反应及其影响因素。
BMC Immunol. 2024 Jan 13;25(1):5. doi: 10.1186/s12865-024-00596-1.
Zotero 插件